AstraZeneca plc (AZN) Given a GBX 5,300 Price Target at BNP Paribas

AstraZeneca plc (LON:AZN) received a GBX 5,300 ($68.45) target price from stock analysts at BNP Paribas in a research note issued on Monday. The firm currently has a “neutral” rating on the biopharmaceutical company’s stock. BNP Paribas’ price objective would indicate a potential upside of 10.65% from the company’s previous close.

AZN has been the subject of several other research reports. HSBC Holdings plc restated a “reduce” rating and issued a GBX 4,100 ($52.95) price target on shares of AstraZeneca plc in a research note on Monday. UBS AG set a GBX 5,150 ($66.51) price target on AstraZeneca plc and gave the stock a “neutral” rating in a research note on Tuesday, June 27th. Goldman Sachs Group, Inc. (The) set a GBX 3,900 ($50.37) price target on AstraZeneca plc and gave the stock a “sell” rating in a research note on Saturday, May 20th. Barclays PLC restated an “overweight” rating and issued a GBX 5,500 ($71.03) price target on shares of AstraZeneca plc in a research note on Tuesday, August 1st. Finally, Citigroup Inc. restated a “buy” rating and issued a GBX 6,000 ($77.49) price target on shares of AstraZeneca plc in a research note on Friday, July 28th. Three research analysts have rated the stock with a sell rating, nine have given a hold rating and ten have issued a buy rating to the company. The company has an average rating of “Hold” and an average price target of GBX 4,963.82 ($64.11).

AstraZeneca plc (AZN) opened at 4884.00 on Monday. The firm has a 50-day moving average price of GBX 4,593.39 and a 200-day moving average price of GBX 4,871.66. The company’s market cap is GBX 61.83 billion. AstraZeneca plc has a 52 week low of GBX 3,996.00 and a 52 week high of GBX 5,520.00.

AstraZeneca plc (LON:AZN) last posted its quarterly earnings results on Wednesday, July 26th. The biopharmaceutical company reported $1.86 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.85 by $1.01. AstraZeneca plc had a return on equity of 14.36% and a net margin of 8.83%. Equities research analysts anticipate that AstraZeneca plc will post $3.75 EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This news story was first posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this news story on another website, it was copied illegally and reposted in violation of US & international trademark and copyright law. The correct version of this news story can be accessed at https://sportsperspectives.com/2017/09/11/astrazeneca-plc-azn-given-a-gbx-5300-price-target-at-bnp-paribas.html.

In other AstraZeneca plc news, insider Nazneen Rahman acquired 39 shares of the company’s stock in a transaction dated Thursday, July 27th. The stock was purchased at an average price of GBX 4,370 ($56.44) per share, with a total value of £1,704.30 ($2,201.08).

About AstraZeneca plc

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Analyst Recommendations for AstraZeneca plc (LON:AZN)

Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply